BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Bolsters Scientific Leadership Ahead of BiTAC(R) Clinical Development

VERAXA Biotech (NASDAQ: VRXA) recently appointed antibody therapeutics specialist Dr. Christoph Erkel as its chief scientific officer, taking responsibility for advancing the company’s proprietary BiTAC(R) technology and broader oncology pipeline toward clinical development. The company’s lead BiTAC-TCE program uses a conditionally active, dual-targeting approach designed to selectively activate T cells against cancer cells while potentially limiting effects on healthy tissue. Recent scientific advice from Germany’s Paul-Ehrlich-Institute provided additional clarity around the program’s proposed non-clinical development strategy, while preclinical data presented at the AACR Annual Meeting showed selective activity against cells expressing both target molecules. Beyond BiTAC, VERAXA is developing bispecific antibody-drug conjugates and other engineered antibody therapies, positioning the company to pursue multiple approaches to next-generation cancer treatment.

To view the full article, visit https://ibn.fm/dSC1p

About VERAXA Biotech AG

VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, VERAXA is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research and cutting-edge technology. For regular updates about VERAXA Biotech, visit www.VERAXA.com.

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

This contant was orignally distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Bolsters Scientific Leadership Ahead of BiTAC(R) Clinical Development.